Helix shareholders approve all proposals for business combination with BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics, Inc.

Business Combination Proposal approved: 17.3M FOR, 2.1M AGAINST (82.55% quorum).
Domestication to Delaware, new charter and bylaws, name change to BridgeBio Oncology Therapeutics Inc. approved.
All 9 director nominees elected unanimously with 19.4M votes each; effective at closing.
2025 Stock Option and Incentive Plan and Employee Stock Purchase Plan both approved by shareholders.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.